ArticleBio-protocol2026
A Versatile In Vitro Quantitative Assay for Macrophage Efferocytosis in Diverse Research Applications.
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage efferocytosis is a previously unrecognized key pathogenic event, engulfing apoptotic targets, preventing inflammation and necrosis, and maintaining immune homeostasis. The phagocytic function can be disrupted by harmful factors and toxic substances. This protocol describes a versatile visualized in vitro method that can be used for the detection of general efferocytosis. This method is applicable to a wide range of research scenarios. As a representative application, it can be used to evaluate macrophage efferocytosis dysfunction in diseases linked to harmful exposures, including atherosclerosis, chronic inflammation, and malignant tumors. Among them, the detection of the effects of oxidized low-density lipoprotein (ox-LDL) and arsenite on macrophage efferocytosis capacity is an exemplary application of this protocol. Primary macrophages collected from mice were labeled with a cell-tracking dye and exposed to ox-LDL or arsenite, then co-cultured with apoptotic thymocytes or hepatocytes (labeled with another cell-tracking dye) for 2 h at a ratio of 5:1. Macrophage efferocytosis was visualized using a laser confocal microscope. The results indicate that arsenite impaired macrophage efferocytosis, leading to insufficient clearance of apoptotic thymocytes or hepatocytes. This method can be extended to subsequent studies, including those involving different types of phagocytes, apoptotic cell models, and research related to exposure to various factors. Key features • This protocol harvests primary mouse macrophages, treats them with different factors (ox-LDL, sodium arsenite), and assesses efferocytosis of apoptotic/necrotic thymocytes or hepatocytes. • Dye-swap red-green staining eliminates fluorescence interference and staining bias and validates dye effects on efferocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.